Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
- PMID: 31189048
- DOI: 10.1056/NEJMc1903943
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
Comment in
-
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943. N Engl J Med. 2019. PMID: 31189049 No abstract available.
Comment on
-
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. N Engl J Med. 2019. PMID: 30786188 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources